Peroxisome proliferator-activated receptor-delta agonist ameliorated inflammasome activation in nonalcoholic fatty liver disease

World Journal of Gastroenterology

Volumn 21, Issue 45, 2015, Pages 12787-12799

  Lee, Hyun Jung ^a   Yeon, Jong Eun ^a   Ko, Eun Jung ^a   Yoon, Eileen L ^a   Suh, Sang Jun ^a   Kang, Keunhee ^a   Kim, Hae Rim ^a   Kang, Seoung Hee ^a   Yoo, Yang Jae ^a   Je, Jihye ^a   Lee, Beom Jae ^a   Kim, Ji Hoon ^a   Seo, Yeon Seok ^a   Yim, Hyung Joon ^a   Byun, Kwan Soo ^a  

^a Korea University College of Medicine   (South Korea)

Author keywords

Inflammasome; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis; Nucleotide binding and oligomerization domain like receptor; Peroxisome proliferator activated receptors delta

Indexed keywords

CRYOPYRIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE ALPHA; INFLAMMASOME; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; LIPOPOLYSACCHARIDE; MESSENGER RNA; PALMITIC ACID; PROTEIN; PROTEIN NLRP10; PROTEIN NLRP6; PROTEIN SERINE THREONINE KINASE; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; [2 METHYL 4 [4 METHYL 2 (4 TRIFLUOROMETHYLPHENYL) 5 THIAZOLYLMETHYLTHIO]PHENOXY]ACETIC ACID; ANTIINFLAMMATORY AGENT; AUTACOID; GLUCOSE BLOOD LEVEL; LIPOPOLYSACCHARIDE, ESCHERICHIA COLI O111 B4; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; THIAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; FATTY LIVER; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; HEPG2 CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIPID DIET; LIVER; LIVER FUNCTION; MALE; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; OLIGOMERIZATION; OXIDATIVE STRESS; PROTEIN EXPRESSION; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CELL PROTECTION; DISEASE MODEL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HEP-G2 CELL LINE; LIVER CELL; METABOLISM; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOLOGY; SIGNAL TRANSDUCTION; TIME FACTOR;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BLOOD GLUCOSE; CYTOPROTECTION; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; HEP G2 CELLS; HEPATOCYTES; HUMANS; INFLAMMASOMES; INFLAMMATION MEDIATORS; LIPOPOLYSACCHARIDES; LIVER; MALE; MICE, INBRED C57BL; NON-ALCOHOLIC FATTY LIVER DISEASE; OXIDATIVE STRESS; PALMITIC ACID; PPAR DELTA; SIGNAL TRANSDUCTION; THIAZOLES; TIME FACTORS;

EID: 84948972849     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v21.i45.12787     Document Type: Article

References (41)

1. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011; 34: 274-285 [PMID: 21623852 DOI: 10. 1111/j. 1365-2036. 2011. 04724. x]
2. Vuppalanchi R, Chalasani N. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management. Hepatology 2009; 49: 306-317 [PMID: 19065650 DOI: 10. 1002/hep. 22603]
3. Musso G, Gambino R, Cassader M, Pagano G. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med 2011; 43: 617-649 [PMID: 21039302 DOI: 10. 3109/0785 3890. 2010. 518623]
4. Abenavoli L, Milic N, Peta V, Alfieri F, De Lorenzo A, Bellentani S. Alimentary regimen in non-alcoholic fatty liver disease: Mediterranean diet. World J Gastroenterol 2014; 20: 16831-16840 [PMID: 25492997 DOI: 10. 3748/wjg. v20. i45. 16831]
5. Farrell GC, van Rooyen D, Gan L, Chitturi S. NASH is an Inflammatory Disorder: Pathogenic, Prognostic and Therapeutic Implications. Gut Liver 2012; 6: 149-171 [PMID: 22570745 DOI: 10. 5009/gnl. 2012. 6. 2. 149]
6. Neuschwander-Tetri BA. Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites. Hepatology 2010; 52: 774-788 [PMID: 20683968 DOI: 10. 1002/hep. 23719]
7. Rolo AP, Teodoro JS, Palmeira CM. Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis. Free Radic Biol Med 2012; 52: 59-69 [PMID: 22064361 DOI: 10. 1016/j. freeradbiomed. 2011. 10. 003]
8. Carabelli J, Burgueño AL, Rosselli MS, Gianotti TF, Lago NR, Pirola CJ, Sookoian S. High fat diet-induced liver steatosis promotes an increase in liver mitochondrial biogenesis in response to hypoxia. J Cell Mol Med 2011; 15: 1329-1338 [PMID: 20629985 DOI: 10. 1111/j. 1582-4934. 2010. 01128. x]
9. Musso G, Gambino R, Cassader M, Pagano G. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology 2010; 52: 79-104 [PMID: 20578268 DOI: 10. 1002/hep. 23623]
10. Abenavoli L, Greco M, Nazionale I, Peta V, Milic N, Accattato F, Foti D, Gulletta E, Luzza F. Effects of Mediterranean diet supplemented with silybin-vitamin E-phospholipid complex in overweight patients with non-alcoholic fatty liver disease. Expert Rev Gastroenterol Hepatol 2015; 9: 519-527 [PMID: 25617046 DOI: 10. 1586/17474124. 2015. 1004312]
11. Rosselli MS, Burgueño AL, Carabelli J, Schuman M, Pirola CJ, Sookoian S. Losartan reduces liver expression of plasminogen activator inhibitor-1 (PAI-1) in a high fat-induced rat nonalcoholic fatty liver disease model. Atherosclerosis 2009; 206: 119-126 [PMID: 19230890 DOI: 10. 1016/j. atherosclerosis. 2009. 01. 026]
12. Szabo G, Csak T. Inflammasomes in liver diseases. J Hepatol 2012; 57: 642-654 [PMID: 22634126 DOI: 10. 1016/j. jhep. 2012. 03. 035]
13. Kubes P, Mehal WZ. Sterile inflammation in the liver. Gastroenterology 2012; 143: 1158-1172 [PMID: 22982943 DOI: 10. 1053/j. gastro. 2012. 09. 008]
14. Martinon F. Signaling by ROS drives inflammasome activation. Eur J Immunol 2010; 40: 616-619 [PMID: 20201014 DOI: 10. 1002/ eji. 200940168]
15. Stienstra R, Tack CJ, Kanneganti TD, Joosten LA, Netea MG. The inflammasome puts obesity in the danger zone. Cell Metab 2012; 15: 10-18 [PMID: 22225872 DOI: 10. 1016/j. cmet. 2011. 10. 011]
16. Vandanmagsar B, Youm YH, Ravussin A, Galgani JE, Stadler K, Mynatt RL, Ravussin E, Stephens JM, Dixit VD. The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat Med 2011; 17: 179-188 [PMID: 21217695 DOI: 10. 1038/nm. 2279]
17. Henao-Mejia J, Elinav E, Jin C, Hao L, Mehal WZ, Strowig T, Thaiss CA, Kau AL, Eisenbarth SC, Jurczak MJ, Camporez JP, Shulman GI, Gordon JI, Hoffman HM, Flavell RA. Inflammasomemediated dysbiosis regulates progression of NAFLD and obesity. Nature 2012; 482: 179-185 [PMID: 22297845 DOI: 10. 1038/ nature10809]
18. Wen H, Gris D, Lei Y, Jha S, Zhang L, Huang MT, Brickey WJ, Ting JP. Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling. Nat Immunol 2011; 12: 408-415 [PMID: 21478880 DOI: 10. 1038/ni. 2022]
19. Poulsen Ll, Siersbk M, Mandrup S. PPARs: fatty acid sensors controlling metabolism. Semin Cell Dev Biol 2012; 23: 631-639 [PMID: 22273692 DOI: 10. 1016/j. semcdb. 2012. 01. 003]
20. Tailleux A, Wouters K, Staels B. Roles of PPARs in NAFLD: potential therapeutic targets. Biochim Biophys Acta 2012; 1821: 809-818 [PMID: 22056763 DOI: 10. 1016/j. bbalip. 2011. 10. 016]
21. Barroso E, Rodríguez-Calvo R, Serrano-Marco L, Astudillo AM, Balsinde J, Palomer X, Vázquez-Carrera M. The PPAR?/? activator GW501516 prevents the down-regulation of AMPK caused by a high-fat diet in liver and amplifies the PGC-1?-Lipin 1-PPAR? pathway leading to increased fatty acid oxidation. Endocrinology 2011; 152: 1848-1859 [PMID: 21363937 DOI: 10. 1210/en. 2010-1468]
22. Buchner DA, Burrage LC, Hill AE, Yazbek SN, O'Brien WE, Croniger CM, Nadeau JH. Resistance to diet-induced obesity in mice with a single substituted chromosome. Physiol Genomics 2008; 35: 116-122 [PMID: 18628339 DOI: 10. 1152/ physiolgenomics. 00033. 2008]
23. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS, Unalp-Arida A, Yeh M, McCullough AJ, Sanyal AJ. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-1321 [PMID: 15915461 DOI: 10. 1002/ hep. 20701]
24. Wang S, Zhang M, Liang B, Xu J, Xie Z, Liu C, Viollet B, Yan D, Zou MH. AMPKalpha2 deletion causes aberrant expression and activation of NAD(P)H oxidase and consequent endothelial dysfunction in vivo: role of 26S proteasomes. Circ Res 2010; 106: 1117-1128 [PMID: 20167927 DOI: 10. 1161/ CIRCRESAHA. 109. 212530]
25. Normand S, Delanoye-Crespin A, Bressenot A, Huot L, Grandjean T, Peyrin-Biroulet L, Lemoine Y, Hot D, Chamaillard M. Nod-like receptor pyrin domain-containing protein 6 (NLRP6) controls epithelial self-renewal and colorectal carcinogenesis upon injury. Proc Natl Acad Sci USA 2011; 108: 9601-9606 [PMID: 21593405 DOI: 10. 1073/pnas. 1100981108]
26. Kempster SL, Belteki G, Forhead AJ, Fowden AL, Catalano RD, Lam BY, McFarlane I, Charnock-Jones DS, Smith GC. Developmental control of the Nlrp6 inflammasome and a substrate, IL-18, in mammalian intestine. Am J Physiol Gastrointest Liver Physiol 2011; 300: G253-G263 [PMID: 21088234 DOI: 10. 1152/ ajpgi. 00397. 2010]
27. Masters SL, Dunne A, Subramanian SL, Hull RL, Tannahill GM, Sharp FA, Becker C, Franchi L, Yoshihara E, Chen Z, Mullooly N, Mielke LA, Harris J, Coll RC, Mills KH, Mok KH, Newsholme P, Nuñez G, Yodoi J, Kahn SE, Lavelle EC, O'Neill LA. Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1? in type 2 diabetes. Nat Immunol 2010; 11: 897-904 [PMID: 20835230 DOI: 10. 1038/ni. 1935]
28. Csak T, Ganz M, Pespisa J, Kodys K, Dolganiuc A, Szabo G. Fatty acid and endotoxin activate inflammasomes in mouse hepatocytes that release danger signals to stimulate immune cells. Hepatology 2011; 54: 133-144 [PMID: 21488066 DOI: 10. 1002/hep. 24341]
29. Miura K, Yang L, van Rooijen N, Brenner DA, Ohnishi H, Seki E. Toll-like receptor 2 and palmitic acid cooperatively contribute to the development of nonalcoholic steatohepatitis through inflammasome activation in mice. Hepatology 2013; 57: 577-589 [PMID: 22987396 DOI: 10. 1002/hep. 26081]
30. Coll T, Alvarez-Guardia D, Barroso E, Gómez-Foix AM, Palomer X, Laguna JC, Vázquez-Carrera M. Activation of peroxisome proliferator-activated receptor-{delta} by GW501516 prevents fatty acid-induced nuclear factor-{kappa}B activation and insulin resistance in skeletal muscle cells. Endocrinology 2010; 151: 1560-1569 [PMID: 20185762 DOI: 10. 1210/en. 2009-1211]
31. Lee CH, Olson P, Hevener A, Mehl I, Chong LW, Olefsky JM, Gonzalez FJ, Ham J, Kang H, Peters JM, Evans RM. PPARdelta regulates glucose metabolism and insulin sensitivity. Proc Natl Acad Sci USA 2006; 103: 3444-3449 [PMID: 16492734 DOI: 10. 1073/pnas. 0511253103]
32. Collino M, Benetti E, Rogazzo M, Mastrocola R, Yaqoob MM, Aragno M, Thiemermann C, Fantozzi R. Reversal of the deleterious effects of chronic dietary HFCS-55 intake by PPAR-? agonism correlates with impaired NLRP3 inflammasome activation. Biochem Pharmacol 2013; 85: 257-264 [PMID: 23103566 DOI: 10. 1016/j. bcp. 2012. 10. 014]
33. Sid B, Verrax J, Calderon PB. Role of AMPK activation in oxidative cell damage: Implications for alcohol-induced liver disease. Biochem Pharmacol 2013; 86: 200-209 [PMID: 23688501 DOI: 10. 1016/j. bcp. 2013. 05. 007]
34. Bays HE, Schwartz S, Littlejohn T, Kerzner B, Krauss RM, Karpf DB, Choi YJ, Wang X, Naim S, Roberts BK. MBX-8025, a novel peroxisome proliferator receptor-delta agonist: lipid and other metabolic effects in dyslipidemic overweight patients treated with and without atorvastatin. J Clin Endocrinol Metab 2011; 96: 2889-2897 [PMID: 21752880 DOI: 10. 1210/jc. 2011-1061]
35. Cariou B, Zaër Y, Staels B, Bruckert E. Effects of the new dual PPAR ?/? agonist GFT505 on lipid and glucose homeostasis in abdominally obese patients with combined dyslipidemia or impaired glucose metabolism. Diabetes Care 2011; 34: 2008-2014 [PMID: 21816979 DOI: 10. 2337/dc11-0093]
36. Nagasawa T, Inada Y, Nakano S, Tamura T, Takahashi T, Maruyama K, Yamazaki Y, Kuroda J, Shibata N. Effects of bezafibrate, PPAR pan-agonist, and GW501516, PPARdelta agonist, on development of steatohepatitis in mice fed a methionine-and choline-deficient diet. Eur J Pharmacol 2006; 536: 182-191 [PMID: 16574099 DOI: 10. 1016/j. ejphar. 2006. 02. 028]
37. Cariou B, Hanf R, Lambert-Porcheron S, Zaër Y, Sauvinet V, Noël B, Flet L, Vidal H, Staels B, Laville M. Dual peroxisome proliferator-activated receptor ?/? agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects. Diabetes Care 2013; 36: 2923-2930 [PMID: 23715754 DOI: 10. 2337/dc12-2012]
38. de Lange P, Lombardi A, Silvestri E, Goglia F, Lanni A, Moreno M. Peroxisome Proliferator-Activated Receptor Delta: A Conserved Director of Lipid Homeostasis through Regulation of the Oxidative Capacity of Muscle. PPAR Res 2008; 2008: 172676 [PMID: 18815630 DOI: 10. 1155/2008/172676]
39. Kudo H, Takahara T, Yata Y, Kawai K, Zhang W, Sugiyama T. Lipopolysaccharide triggered TNF-alpha-induced hepatocyte apoptosis in a murine non-alcoholic steatohepatitis model. J Hepatol 2009; 51: 168-175 [PMID: 19446916 DOI: 10. 1016/ j. jhep. 2009. 02. 032]
40. Shanab AA, Scully P, Crosbie O, Buckley M, O'Mahony L, Shanahan F, Gazareen S, Murphy E, Quigley EM. Small intestinal bacterial overgrowth in nonalcoholic steatohepatitis: association with toll-like receptor 4 expression and plasma levels of interleukin 8. Dig Dis Sci 2011; 56: 1524-1534 [PMID: 21046243 DOI: 10. 1007/ s10620-010-1447-3]
41. Takahashi Y, Soejima Y, Fukusato T. Animal models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol 2012; 18: 2300-2308 [PMID: 22654421 DOI: 10. 3748/wjg. v18. i19. 2300]